Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
777.080.1%
QQQ
731.230.11%
BTC/USD
62675.151.1828%
DIA
537.290.12%
GLD
402.740.95%
TLT
82.170.5%

Innate Pharma SA

IPHANASDAQ
Trade with Public
Trade with Public
$2.20
-0.33-13.21%
Last update: Aug 14, 10:30 AM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareStock Report

Innate Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Innate Pharma (IPHA).

Price Target Range — 13 Quarters

Analyst Consensus — 3 Analysts

2Buy
1Hold
Consensus RatingBuy# Analysts3Avg. Consensus PT$7Upside to Avg. PT+195.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026BTIGJeet Mukherjee PT RaiseBuy$8→$9
Aug 10, 2026HC Wainwright & Co.Swayampakula RamakanthPT RaiseBuy$5→$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9

BTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $8 to $9.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $5 to $7.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $5 price target.
Benzinga Newsdesk

PRO
BTIG Assumes Innate Pharma at Buy, Announces Price Target of $8

BTIG analyst Jeet Mukherjee assumes Innate Pharma (NASDAQ:IPHA) with a Buy rating and announces Price Target of $8.
Benzinga Newsdesk

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

Avi Kapoor

PRO
HC Wainwright & Co. Upgrades Innate Pharma to Buy, Announces $5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth upgrades Innate Pharma (NASDAQ:IPHA) from Neutral to Buy and announces $5 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved